The U.S. Food and Drug Administration has approved Rasonque (daraxonrasib), a first-in-class RAS inhibitor, for the treatment of the most common form of metastatic pancreatic cancer. Arriving months ahead of schedule, this targeted therapy offers a vital new treatment option for patients battling advanced stages of the disease.